Intravenous methylprednisolone pulse therapy in the treatment of Graves' ophthalmopathy

Hormone and Metabolic Research

Volumn 30, Issue 2, 1998, Pages 93-98

  Matejka, G ^a   Verges B ^a   Vaillant, G ^a   Petit, J M ^a   Brun Pacaud, A ^a   Rudoni, S ^a   Brun, J M ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Graves' disease; Graves' ophthalmopathy; Methylprednisolone; Pulse therapy

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VISUAL ACUITY;

EID: 0031884794     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-978843     Document Type: Article

References (38)

1. Bartalena L, Martino E, Marocci C, Bogazzi F, Panicucci M, Velluzzi F, et al. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 1989; 12: 733-7
2. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves' ophthalmopathy and smoking. Lancet 1990, 335: 1261 -3
3. Weetman AP, Zhang L, Webb S, Shine B. Analysis of HLA-DQB, HLA-DPB alleles in Graves' disease by oligonucleotide probing of enzymatically amplified DNA. Clin Endocrinol 1990; 33: 65 -71
4. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993; 329: 1468-75
5. Burch BB, Wartofsky L. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management. Endocrine Rev 1993; 14: 747-93
6. Heufelder AE. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol 1995; 132: 532-41
7. Peterson IA, Kriss JP, Mc Dougall IR, Donaldson SS. Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 1990; 19: 254-64
8. Karlsson FA, Dahlberg PA, Jansson R, Enoksson P, Thorgeirsson E, Tottermann T. A pilot study of cyclosporin in endocrine ophthalmopathy. In Schindler Editions: Cyclosporin in autoimmune diseases. Berlin: Springer, 1985: 242-6
9. Landgraf R, Witte A, Mark LA, Boegen KP, Hasenfratz G, Pickardt CR. Treatment of Graves' ophthalmopathy with cyclosporin. In Schindler Editions: Cyclosporin in autoimmune diseases. Berlin: Springer, 1985: 235-41
10. Mc Gregor AM, Beck M, Weetman AP, Hall R. Cyclosporin in the management of Graves' ophthalmopathy. In Schindler Editions: Cyclosporin in autoimmune diseases. Berlin: Springer, 1985: 229-34
11. Prummel MF, Mourits MP, Berghout A, Krenning EP, Van der Gaag R, Koorneef L, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989; 321: 1353-9
12. Prummel MF, Mourits MP, Blank L, Berghout A, Koorneef L, Wiersinga WM. Randomised double-blind trial of prednisolone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993; 342: 949-54
13. Wiersinga WM. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid 1992; 2: 229-33
14. Antonelli A, Saracino A, Alberti B, Canapicchi R, Cartel F, Lepri A, et al. High dose intravenous immunoglobulin treatment in Graves'ophthalmopathy. Acta Endocrinol 1992; 126: 13-23
15. Dandona P, Marshall NJ, Bidey SP, Nathan AW, Havard CWH. Successful treatment of exophthalmos and pretibial myxedema with plasmapheresis. BMJ 1979; 1: 374-6
16. Dandona P, Marshall NJ, Bidey SP, Nathan AW, Havard CWH. Exophthalmos and pretibial myxedema not responding to plasmapheresis. BMJ 1979; 2: 667-8
17. Lewis RA, Slater N, Croft DN. Exophthalmos and pretibial myxedema not responding to plasmapheresis. BMJ 1979; 2: 390-1
18. Cathcart ES, Scheinberg MA, Idelson BA, Couser WG. Beneficial effects of methylprednisolone pulse therapy in diffuse proliferative lupus nephritis. Lancet 1976; 1: 163-6
19. Liebling MR, Leib E, Mc Laughlin K. Pulse methylprednisolone in rheumatoid arthritis. A double-blind crossover trial. Ann Intern Med 1981; 94: 21-6
20. Kimberly LP. Pulse Methylprednisolone therapy in SLE. Rheum Dis Clin North Am 1982; 8: 261-78
21. Classification of eye changes of Graves' disease. Thyroid 1992; 2: 235-6
22. Werner SC. Classification of the eye changes of Graves' disease. J Clin Endocrinol Metab 1969; 29: 982-4
23. Werner SC. Modification of the classification eye changes of Graves' disease: recommendations of the ad hoc committee of the American Thyroid Association. J Clin Endocrinol Metab 1977; 44: 203-4
24. Mourits MP, Koorneef L, Wiersinga WM, Prummel MF, Berghout A, Van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy; a novel approach. Br J Ophthalmol 1989; 73: 639-44
25. Kinsell LW, Partridge JW, Foreman N. The use of ACTH and cortisone in the treatment and in the differential diagnosis of malignant exophtalmos: a preliminary report. Ann Intern Med 1953; 38: 913-7
26. Werner SC. Prednisone in emergency treatment of malignant exophtalmos. Lancet 1966; 1: 1004-7
27. Kendall-Taylor P, Crombie AL, Stephensson AM, Hardwick M, Hall K. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988; 297: 1574-8
28. Hamilton HE, Chultz RO, Degowin EL. The endocrine eye lesion in hyperthyroidism. Its incidence and course in 165 patients treated for thyrotoxicosis with iodine-131. Arch Intern Med 1960; 105: 675-85
29. Streeten DHP, Anderson GH, Reed GF, Woo P. Prevalence, natural history and surgical treatment of exophthalmos. Clin Endocrinol 1987; 27: 125-33
30. Garret R, Paulus H. Complications of intravenous methylprednisolone pulse therapy. Arthr Rheum 1980; 23: 677-80
31. Freedman MD, Schoket AL, Chapel N, Gerber JC. Anaphylaxis after intravenous methylprednisolone administration. JAMA 1981: 983-4
32. Williams I. A survey of pulsed intravenous methylprednisolone in the treatment of rheumatoid disease. Geriatric Med Today 1984; 3: 97-108
33. Dandona P, Havard CWH, Mier A. Methylprednisolone and Graves' ophthalmopathy. BMJ 1989; 298: 830
34. Guy JR, Fagien S, Donovan JP, Rubin ML. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology 1989; 96: 1048-53
35. Nagayama Y, Izumi M, Kiriyama T, Yokoyama N, Morita S, Kakezono F, et al. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy. Acta Endocrinol 1987; 116: 513-8
36. Kendall-Taylor P, Crombie AL, Perros P. High dose intravenous methylprednisolone pulse therapy in severe thyroid-associated ophthalmopathy. Thyroid 1992; 2: S29
37. Hiromatsu Y, Tanaka K, Sato M, Kuroki T, Nonaka K, Kojima K, et al. Intravenous MP pulse therapy for Graves' ophthalmopathy. Endocrine 1993; 40: 63-72
38. Mori S, Yoshikawa N, Horimoto M, Yoshimura M, Nishikawa M, et al. Thyroid stimulating antibody in sera of Graves' ophthalmopathy patients as a possible marker for predicting the efficacy of methylprednisolone pulse therapy. Endocrine J 1995; 42: 441-8